All News

knee.injx_.lat_.jpg

Intraarticular IL-1Ra Gene Therapy in Knee Osteoarthritis

Jack Cush, MD

De la Vega et al. have published in Science Translational Medicine the efficacy of an IL-1Ra gene therapy in adults with knee osteoarthritis (OA).

Read Article
brain headache neuro

Transcranial Stimulation is Effective in Fibromyalgia

Jack Cush, MD

A randomized, controlled clinical trial in fibromyalgia (FM) has shown the efficacy of transcranial direct current stimulation (A-tDCS) (along with exercise and pain neuroscience education [PNE]), in alleviating the pain. 

Read Article
GCA,woman

Secukinumab Use in Refractory Giant Cell Arteritis

Jack Cush, MD

In 2023, the phase 2 TitAIN study showed that the effectiveness and safety of secukinumab in 52 patients with giant cell arteritis (GCA) who had an inadequate response to tocilizumab.

Read Article
early.ra_.2.jpg

2025 EULAR/ACR Risk Stratification Criteria for At-Risk Arthralgia

Jack Cush, MD

A collaborative EULAR/ACR expert panel has established criteria for arthralgia patients at risk (clinically suspect arthralgia) to progress to chronic rheumatoid arthritis (RA).

Read Article
RheumNow Podcast square

MTX Fails Knee OA (6.6.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com

Read Article
labs2.jpg

HLA-B27 Testing in Practice

Jack Cush, MD

Analysis of testing for human leukocyte antigen B27 (HLA-B27) in a teaching center shows HLA-B27 testing was frequently performed by rheumatologists and nonrheumatologists for a broad spectrum of indications and primarily as a screening test. 

Read Article
RA ILD RTX lung

Psoriatic Arthritis at Risk for Interstitial Lung Disease

Jack Cush, MD

A TriNetX EHR study shows that psoriatic arthritis, but not psoriasis, patients are at increased risk for interstitial lung disease (ILD).

Read Article
Risk of #VTE in #rheumatoid #arthritis Is it better over last 25 yrs? 👎 Olmstead County population study of #RA Pts vs matched controls ⬆️VTE in RA ⬆️VTE w active RA But not change in rates of #DVT & #PE since 2000 Why? 🤔 Abst#OP0070 @rheumnow #EULAR2025 @eular_org https://t.co/eSyjfjVqtY

Links:

Janet Pope Janetbirdope ( View Tweet)
UK Natl Early Inflammatory Arthritis Audit (5/18-11/19) compared 2120 PsA & RA (1:1). PsA had longer Sx to referral wait (112 v 89 days; HR 0.87), longer delay in Dx (HR 0.8), PsA less DMARD use at baseline (54% v 69%) & higher DAS28 results at 3 mos (+0.27) https://t.co/zyubhGxw47
Dr. John Cush RheumNow ( View Tweet)
Single center Italian study of 414 JIA q6mos (for 2 yrs) used machine learning & 68 clinical variables to predict clinically inactive Dz (CID). Best predictive of CID at 2 yrs was 1) physician’s global assessment, followed by 2) active joint counts (using data from 0-12 mos) https://t.co/2SEH1a85Nj
Dr. John Cush RheumNow ( View Tweet)
POSTER HALL PRESENTATION: Sponsored by AbbVie Medical Affairs + Health Impact. 🔍Real-world outcomes in patients with RA remaining on first-line TNFi 📽️See Dr. Charles-Schoeman discuss subsequent outcomes in patients who did or did not achieve response at 3 or 6 months https://t.co/8RmcigG7SF
Dr. John Cush RheumNow ( View Tweet)
Systematic review of fibromyalgia & sleep quality - 47 RCTs, 11094 pts showed CBT for insomnia had a significant improvement in sleep quality; but CBT for pain had no impact. Only moderate improvement w/ pregabalin, sodium oxybate; but no effect w/ amitriptyline, milnacipran, https://t.co/bArizMLGR8
Dr. John Cush RheumNow ( View Tweet)
The global regenerative medicine market is estimated to be valued at USD 9.8 billion in 2025 and is projected to reach USD 22.05 billion by 2035 -- AMAZING, especially since the (lack of) science and most evidence does NOT support it's efficacy! https://t.co/2D2K1jrQZH https://t.co/UBMPgeZ25G

Links:

Dr. John Cush RheumNow ( View Tweet)
The American Heart Association just published their alcohol recommendations today which line up with the report by the National Academies. Moderate EtOH intake, up to 7 drinks per week (1/day), is without risk (and may be beneficial for cardiovascular outcomes) @American_Heart https://t.co/7c0IlmgZiv

Links:

Eric Topol EricTopol ( View Tweet)
Psoriatic Arthritis at Risk for Interstitial Lung Disease A TriNetX EHR study shows that psoriatic arthritis (PsA), but not Psoriasis (PsO), patients are at increased risk for interstitial lung disease (ILD). https://t.co/2zuxF1PY3Q. https://t.co/r28dY3T8nO

Links:

Dr. John Cush RheumNow ( View Tweet)
Uncontrolled pilot trial of frequency specific microcurrent treatment given to 17 pts w/ Raynaud’s & systemic sclerosis. Microcurrent Rx given for 45-60 min over 1-2d; w/ average improvement of 40% in hand function & Raynauds improvement ~18% p .016)- RCT needed!! https://t.co/4OUeODuj8Q
Dr. John Cush RheumNow ( View Tweet)
Denosumab and Osteoporosis - A JAMA Review An overview of denosumab use in osteoporosis (OP) by Bauer and Ensrud was published in JAMA https://t.co/3d7Q61nVKM https://t.co/i3DjtcsuWo

Links:

Dr. John Cush RheumNow ( View Tweet)
Systematic review of fibromyalgia & sleep quality - 47 RCTs, 11094 pts showed CBT for insomnia had a significant improvement in sleep quality; but CBT for pain had no impact. Only moderate improvement w/ pregabalin, sodium oxybate; but no effect w/ amitriptyline, milnacipran, https://t.co/AEqbShRh6e
Dr. John Cush RheumNow ( View Tweet)
UK Natl Early Inflammatory Arthritis Audit (5/18-11/19) compared 2120 PsA & RA (1:1). PsA had longer Sx to referral wait (112 v 89 days; HR 0.87), longer delay in Dx (HR 0.8), PsA less DMARD use at baseline (54% v 69%) & higher DAS28 results at 3 mos (+0.27) https://t.co/ObssKGcomq
Dr. John Cush RheumNow ( View Tweet)
Denosumab and Osteoporosis - A JAMA Review An overview of denosumab use in osteoporosis (OP) by Bauer and Ensrud was published in JAMA https://t.co/3d7Q61nVKM https://t.co/PdI235k9jh

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×